Immune to Cancer: The CRI Blog
-
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts
-
ASCO17: Days 4 and 5 Immunotherapy Highlights
Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical…
-
ASCO17: Day 3 Immunotherapy Highlights
Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy…
-
ASCO17: Day 2 Immunotherapy Highlights
Day 2 at the 2017 annual meeting of the American Society of Clinical Oncology further highlighted immunotherapy's…
-
ASCO17: Day 1 Immunotherapy Highlights
Day 1 at the 2017 annual meeting of the American Society of Clinical Oncology demonstrated immunotherapy’s potential…
-
June is Cancer Immunotherapy Month
We love the month of June! The beautiful summer sunshine, the soft breezes…and of course, all the…
-
ASCO17: Exploring the Past, Present, and Future of Immunotherapy
Immunotherapy is poised to shine at ASCO17
-
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.